Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 6/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10969055 | 0.94 | ADRA1A (0.59) | ADRA1AALDH1A1KDM4EHPGDGLA | |
| SCHEMBL2722920 | 0.91 | ADRA1A (0.52) | ADRA1AALDH1A1KDM4EHPGDGLA | |
| SCHEMBL15586581 | 0.87 | ADRA1A (0.49) | ADRA1AALDH1A1KDM4EHPGDGLA | |
| SCHEMBL13274500 | 0.87 | KDM4E (0.53) | ADRA1AALDH1A1KDM4EHPGDGLA | |
| SCHEMBL31741626 | 0.87 | ADRA1A (0.49) | ADRA1AALDH1A1KDM4EHPGDGLA | |
| SCHEMBL835276 | 0.87 | ADRA1A (0.49) | ADRA1AALDH1A1KDM4EHPGDGLA | |
| SCHEMBL19337381 | 0.87 | ADRA1A (0.53) | ADRA1AALDH1A1KDM4EHPGDGLA | |
| SCHEMBL13274485 | 0.83 | ALDH1A1 (0.50) | ADRA1AALDH1A1KDM4EHPGDGLA | |
| SCHEMBL6169404 | 0.82 | KDM4E (0.53) | ADRA1AALDH1A1KDM4EHPGDGLA | |
| SCHEMBL7327510 | 0.82 | ADRA1A (0.49) | ADRA1AALDH1A1KDM4EHPGDGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101772487-B | Thyroid compounds | TORRENT PHARMACEUTICALS LTD | 2014-01-22 | — | — | CN | disclosed |
| US-8378118-B2 | Pyrazole-based thyroid receptor compounds | TORRENT PHARMACEUTICALS LTD. (IN) | 2013-02-19 | — | — | US | disclosed |
| US-20120202816-A1 | NOVEL COMPOUNDS | TORRENT PHARMACEUTICALS, LTD. (IN) | 2012-08-09 | — | — | US | disclosed |
| US-8143424-B2 | Thyroid like compounds | TORRENT PHARMACEUTICALS LTD. (IN) | 2012-03-27 | — | — | US | disclosed |
| EP-2061766-B1 | NOVEL COMPOUNDS | TORRENT PHARMACEUTICALS LTD (IN) | 2010-08-18 | — | — | EP | disclosed |
| US-20100168110-A1 | Novel Compounds | TORRENT PHARMACEUTICALS LTD. (IN) | 2010-07-01 | — | — | US | disclosed |
| EP-2061766-A2 | NOVEL COMPOUNDS | Torrent Pharmaceuticals Ltd (IN) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008149379-A2 | NOVEL COMPOUNDS | TORRENT PHARMACEUTICALS LTD. (IN) | 2008-12-11 | — | — | WO | disclosed |
| WO-2001079209-A2 | DIAZAFLUORENONE IL-8 ANTAGONISTS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
| EP-0190740-B1 | USE OF SUBSTITUTED QUINONE ELECTRON TRANSFER AGENTS IN ANALYTICAL DETERMINATIONS | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1991-11-27 | — | — | EP | disclosed |
| US-4746607-A | MEDICAL DIAGNOSIS, DETECTION OF BACTERIA | EASTMAN KODAK COMPANY (US) | 1988-05-24 | — | — | US | disclosed |
| EP-0190740-A2 | Use of substituted quinone electron transfer agents in analytical determinations | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1986-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202816-A1 | NOVEL COMPOUNDS | TSHR, THRB, GPR119 | ADRA1A 173/4885ALDH1A1 1664/4885KDM4E 3112/4885 |
| US-20100168110-A1 | Novel Compounds | TSHR, THRB, GPR119 | ADRA1A 173/4885ALDH1A1 1664/4885KDM4E 3112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.